Conservative or Operative Therapy in Patients With a Fragility Fracture of the Pelvis

October 2, 2023 updated by: Björn-Christian Link

Conservative or Operative Therapy in Patients With a Fragility Fracture of the Pelvis: a Prospective, Randomized Controlled Trial

In our society the population consists of more elderly patients. Medical treatment needs to be adjusted to this patient group. This research project focusses on patients with a fragility fracture of the pelvis. This results from a minor trauma and can cause a long immobilization period because of severe pain. For FFP type II b and II c there is no consensus on the best treatment option. Either a surgical minimal invasive sacroiliac osteosynthesis or conservative treatment is a possibility. Of course, both treatment options have pros and cons. This research project will randomize all patients with a FFP IIb or IIc fracture in either surgical or conservative treatment. These treatments will be evaluated at the follow-ups, 4 weeks, 4 months and 1 year after trauma. This will be evaluated with the DEMMI, Accelerometer, EQ-5D (EuroQol Quality of Live Questionnaire), radiological results, range of motion, pain-levels and reporting any postoperative complications or adverse events. Patient will be included over a period of 18 months and will be followed for at least a year. This research project aim to answer the question which treatment option for FFP type IIb and IIc is the most adequate.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Background. Fragility fractures of the pelvis are increasing in incidence. These are osteoporotic fractures, who result from a minor trauma. Typically, the weak osteoporotic bone is fractured, an the ligaments remain intact resulting in an undisplaced or minimally displaced pelvic ring. Fragility fractures of the pelvis can be divided in type I, II, III and IV. For type I the treatment method of choice is conservative. For type III and IV a surgical treatment is necessary. Only the ideal treatment for type II remains unclear. There is no consensus in whether conservative treatment or surgical treatment will have the best outcomes. Surgical treatment mostly means a minimal invasive osteosynthesis. In our hospital we use percutaneous sacroiliac screw fixation with augmentation. The screws used are perforated and fenestrated, allowing for a correct placement an cement augmentation. Preferably, this procedure is performed in our hybrid operation theatre. An intraoperative CT-scan can be performed. This treatment method has proven to be a safe method in literature. On the other hand, surgical treatment, can have complications and risks, especially in the elderly. Conservative treatment consist of mobilisation and physiotherapy. But conservative treatment can be limited because of uncontrolled pain, resulting in a long immobilisation period. Immobilisation in the elderly leads to several complications. This research project will focus on early operative intervention to reduce the immobilisation period and its negative consequences.

Study design. Recruitment of patients will find place in our emergency department and our outpatient clinic. A lot of patients with a FFP type IIb and IIc present themselves at our emergency department due to immobilising pain. All the elderly patient who complain about sacroiliac pain will receive an CT-scan. Literature showed that an conventional x-ray is not sufficient to detect sacroiliac fractures. On the other hand a lot of patient are referred to our outpatient clinic by other hospitals in our region or even general practioners. All these patients, who meet our inclusion criteria, will be asked for informed consent. After informed consent has been collected, patients will be randomised to on of the groups. The first group will receive surgical treatment and the second group will receive conservative treatment. Randomisation is performed with a vending machine. Depending on which soda can comes out, patients are assigned to the groups.

Study intervention. As stated before the are two groups in this research project. Both treatment are standard treatments. Both groups will receive a standard set of co-interventions, such as adequate analgesics and intensive physiotherapy. At our hospital a geriatric trauma centre is established. After discharge or 4 weeks after trauma a first follow-up is planned. This is primary for the treatment evaluation. Then after 4 months are second follow-up is planned with a traumatologist, physiotherapist and a geriatric specialist. At this follow-up several benchmark test are performed, such as the DEMMI, EQ 5D and an accelerometer is explained and given out. Especially this accelerometer will tell us more about the amount of mobilisation or immobilisation at home. The last follow-up will be 1 year after trauma. At all follow-ups radiological controls are performed. These will be conventional x-rays. Only in specific cases, for example prolonged pain, an CT-scan will be performed.

Data and data management. The sample size was based on the expected difference between treatment groups in improvement on the DEMMI score between baseline and 4 months follow-up. Previous studies show that the minimal clinical important difference of the DEMMI score is 10 points. This results in a sample size of 68 patients, accounted for 10% loss to follow-up.

The statistical planned analyses are primary a pearson chi-squared or fishers exact test for categorical variables or a students t or mann-whitney test. However the primary outcome will be analysed using mixed linear models with random effects. The models will be compared usin Akaike information criterium. Missing data will be imputed using multiple imputation. All analyses will be performed using SPSS version 19 or higher. A p value <0.05 is regarded as being statistically significant.

Data is stored on the protected server systems of Hospital of Lucerne. Files containing anonymous data can also be stored on the personal computers of the investigators. Data is recorded on paper and digitally. Questionnaires are on paper, but all the measurements, as the DEMMI score of range of motion will be digitally. Participants can not be identified in the CRF (Case report form). Appropriate corresponding codes are only known and accessible for the investigators.

Upon simple request by the patient, he or she will immediately be withdrawn from the study and no further date will be recorded in the study. It is guaranteed that further treatment will be equal to standard care.

Study Type

Interventional

Enrollment (Estimated)

68

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Informed Consent as documented by signature
  • The fracture must be a fragility fracture. This means absence of high energy trauma.
  • Fragility fracture of the sacrum (FFP II b + c). Involvement of the ventral pelvic ring is not an exclusion criteria.
  • Able to walk 4 meters before fracture

Exclusion Criteria:

  • Patients who had a high energy trauma.
  • FFP I or FFP III+IV were operative therapy is recommended
  • Patient who are not operable according to the anaesthesiologist on call.
  • Open fractures.
  • Revision surgeries.
  • Absent contact information
  • Living abroad and cannot participate in follow-up visits.
  • Withdrawal from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Surgical
Surgical treatment using a minimal invasive surgical method. At our hospital we perform a percutaneous sacroiliac osteosynthesis using cannulated, perforated and fenestrated screws. This procedure is preferably performed in our hybrid operation theatre, which allows for correct placement using an intraoperative CT-scan.
Patients will either be randomized in the surgical or conservative group.
Active Comparator: Conservative
Patients will receive individually tailored physiotherapy and analgesics if necessary.
Patients will either be randomized in the surgical or conservative group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mobility level
Time Frame: 1 year
DEMMI (0-100, 100 is maximal mobility)
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain levels
Time Frame: 1 year
VAS (visual analogue scale, 0-10, 0 means no pain)
1 year
Clinical characteristics
Time Frame: Baseline
Age
Baseline
Clinical characteristics
Time Frame: Baseline
Gender
Baseline
Clinical characteristics
Time Frame: Baseline
ASA-Score (1-6, 1 is a healthy patient)
Baseline
Clinical characteristics
Time Frame: Baseline, 1 year
BMI
Baseline, 1 year
Clinical characteristics
Time Frame: Baseline
Osteoporosis treatment (yes or no)
Baseline
Medication
Time Frame: Baseline, 1 year
Reporting what kind of medications all patients take (including steroids, anticoagulation, pain killers, et cetera)
Baseline, 1 year
Clinical characteristics
Time Frame: Through study completion, an average of 1 year
Surgical related complications
Through study completion, an average of 1 year
Clinical characteristics
Time Frame: after discharge
Length of hospital stay after first admission
after discharge
Clinical characteristics
Time Frame: Baseline
Fracture classification (FFP I - IV)
Baseline
Clinical characteristics
Time Frame: 1 year
FES-1 (falls efficacy scale, 16-64, 16 means no fear of falling, 64 is the maximum)
1 year
Clinical characteristics
Time Frame: 1 year
EQ-5D (0-100, 100 is the best possible health status)
1 year
Clinical characteristics
Time Frame: 1 year
SPPB (short physical performance battery, 0-12, 12 is the best function)
1 year
Mobility level
Time Frame: 1 year
Barthel Index (0-100, 100 is completely independent)
1 year
Mobility level
Time Frame: During 1 week after 4 Months
Accelerometer (this is a device that continously measures the activity level of an patient. It comes in the form of a bracelet)
During 1 week after 4 Months
Mobility level
Time Frame: 1 year
TUG (time up and go test)
1 year
Mobility level
Time Frame: 1 year
5 Chair rise
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2022

Primary Completion (Estimated)

December 30, 2024

Study Completion (Estimated)

December 30, 2025

Study Registration Dates

First Submitted

December 10, 2020

First Submitted That Met QC Criteria

February 5, 2021

First Posted (Actual)

February 8, 2021

Study Record Updates

Last Update Posted (Actual)

October 3, 2023

Last Update Submitted That Met QC Criteria

October 2, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • FFP1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pelvic Fracture

Clinical Trials on Treatment of FFP type IIb and IIc

Subscribe